Clinical Data Summary Pilot Program
The Center for Drug Evaluation and Research (CDER) is committed to improving efficiency and transparency in the drug approval process. Consistent with this goal, CDER has launched a pilot program to assess the feasibility of using a different format to provide required summaries of the safety and effectiveness information that is used to make regulatory decisions. The pilot program will include up to nine recently submitted new drug applications (NDAs). For these applications, if approved, CDER will release portions of the clinical study reports (CSRs) from the sponsor’s NDA along with the action package following approval. The CSRs are made up of summaries of clinical information used in making market approval decisions, and will be included in the information posted at the drug’s entry at Drugs@FDA.
CDER’s goal is to provide a usable summary of clinical evidence. FDA will gather feedback about how useful posting portions of CSRs of the summary data in this format might be for the drug research and development community, medical researchers, and the public. The Agency is also responding to stakeholders’ requests for improved access to usable information. It is FDA’s view that the information contained in the CSR sections that will be posted as part of the pilot is a summary, and FDA will not be posting raw data. The portions of the CSRs that will be posted include information from the study report body, the protocol and amendments, and the statistical analysis plan for each study.
Soon after an approval, CDER will post the CSR sections below and in the relevant entry at Drugs@FDA. For inquiries about the pilot, please contact CDER’s Office of New Drugs at ClinicalSummaryPilot@fda.hhs.gov or 301-796-8686.
Clinical Study Reports
- FDA's Clinical Data Summary Pilot Program: Questions Frequently Asked by Industry
May 2, 2018
- FDA Voice Blog: FDA’s New Pilot Program Aims for More Transparency about New Drug Approvals
March 19, 2018
- FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs
January 16, 2018